# Intravenous Immunoglobulin Market

> Intravenous Immunoglobulin (IVIG) Market Research Report By Application (Immunodeficiency Disorders, Neurological Disorders, Autoimmune Disorders, Infectious Diseases), By End Use (Hospitals, Clinics, Homecare, Pharmaceutical Companies), By Product Type (Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, Combination Therapies), By Source (Human Plasma, Recombinant Techniques) and By Region (North America, Europe, South America, Asia Pacific, Middle East and Africa) -Forecast to 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 6.85%
- **2025:** USD 17.67 Billion
- **2035:** USD 34.33 Billion
- **Key Players:** CSL Behring, Grifols, Takeda, Octapharma, Kedrion Biopharma, Shanghai RAAS, Biotest AG, LFB

**Report ID:** MRFR/HC/2259-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** October 07, 2026

**URL:** https://www.marketresearchfuture.com/reports/intravenous-immunoglobulin-market-3137

---

## Market Summary

As per MRFR analysis, the Intravenous Immunoglobulin Market Size was estimated at 12.39 USD Billion in 2024. The Intravenous Immunoglobulin industry is projected to grow from 12.88 USD Billion in 2025 to 18.99 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 3.96% during the forecast period 2025 - 2035. North America led the market with over 52.46% share, generating around USD 6.5 billion in revenue.
 
The Intravenous Immunoglobulin Market is primarily driven by the increasing prevalence of immunodeficiency and autoimmune disorders, alongside growing adoption of immunotherapy treatments, supported by advancements in plasma-derived therapies that enhance treatment efficacy and expand clinical applications globally.
 
According to the World Health Organization (WHO), autoimmune and chronic diseases contribute significantly to global morbidity, while the Institute for Health Metrics and Evaluation (IHME) reports rising immune-related disorders worldwide. This increasing disease burden is accelerating demand for IVIG therapies to improve immune response and patient outcomes.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising diagnosis of primary immunodeficiency | +1.5% | Global; strongest in North America & Europe | Long-term (≥4 yr) | [14] |
| Label expansion in neurology | +1.3% | North America, Europe | Medium-term (2–4 yr) | [1][15] |
| Plasma collection capacity expansion | +1.1% | North America, Europe, China | Short-term (≤2 yr) | [6][10] |
| Secondary immunodeficiency in hematologic cancer | +0.9% | Global | Medium-term (2–4 yr) | [16] |
| Plasma self-sufficiency programs in emerging economies | +0.8% | Asia-Pacific, Middle East & Africa, South America | Long-term (≥4 yr) | [8] |
| Home-infusion reimbursement expansion | +0.7% | North America | Short-term (≤2 yr) | [3][18] |

### Rising Diagnosis of Primary Immunodeficiency

The Jeffrey Modell Foundation estimates that about 6 million people worldwide live with a primary immunodeficiency and that 70–90% remain undiagnosed [14]. Newborn screening for severe combined immunodeficiency, now standard in all 50 U.S. states, and wider use of genetic panels are moving patients into care earlier. Each diagnosed patient on replacement typically needs 0.4–0.6 g/kg every three to four weeks for life, so diagnosis gains compound into durable, multi-decade gram demand.

### Label Expansion in Neurology

Neurology now consumes more grams than immunology in several mature markets, which reshapes demand in the Intravenous Immunoglobulin (IVIg) Market. CIDP maintenance dosing often runs 1 g/kg every three weeks, roughly double a typical replacement dose [15]. FDA approvals of Panzyga for CIDP and Octagam 10% for dermatomyositis in 2021 widened on-label use [1]. The 2021 EAN/PNS guideline kept immunoglobulin as a first-line CIDP therapy [15].

### Plasma Collection Capacity Expansion

Approximately two-thirds of the plasma fractionated globally is supplied by the United States, which has over 1,000 licensed plasma centers [6]. Operators are implementing nomogram-based devices and automating donor screening; according to CSL, its Rika platform reduces the average donation time by roughly 30% [10]. In 2023, China's authorized collection levels increased to 12,000 tons [17]. The impact is short-term because new plasma produces the final product in 7–12 months.

### Secondary Immunodeficiency in Hematologic Cancer

Patients with chronic lymphocytic leukemia, multiple myeloma, and those treated with CAR-T or BCMA-targeted bispecific antibodies frequently develop hypogammaglobulinemia. In the pivotal teclistamab trial, roughly three-quarters of patients developed low IgG levels, prompting prophylactic replacement in many centres [16]. With seven CAR-T therapies approved in the U.S. by end-2024 and more bispecifics in late-stage trials, secondary immunodeficiency is becoming a material incremental growth channel.

### Plasma Self-Sufficiency Programs in Emerging Economies

WHO guidance published in 2021 urges low- and middle-income countries to fractionate domestic plasma rather than discard it [8]. Egypt's joint venture with Grifols plans 20 plasma donation centres plus local fractionation, and Indonesia has contracted SK Plasma to build a domestic plant. These programs convert previously wasted recovered plasma into accessible IVIg, expanding treated populations where per-capita use is a fraction of Western levels.

### Home-Infusion Reimbursement Expansion

CMS's IVIG items and services benefit, made permanent from January 1, 2024, pays for nursing visits and supplies for Medicare beneficiaries with primary immunodeficiency who infuse at home [3]. Patient surveys from the Immune Deficiency Foundation show strong preference for home or clinic settings [18]. Home administration lowers per-infusion facility costs by an estimated 25–35% versus hospital outpatient delivery, encouraging commercial payers to follow.

## Restraints

## Restraints Impact Analysis

Restraint values are directional estimates of downward pressure on growth in the Intravenous Immunoglobulin (IVIg) Market. Like drivers, they overlap and are not additive.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Plasma supply constraints and rising collection cost | −1.2% | Global | Short-term (≤2 yr) | [6][11] |
| Competition from FcRn inhibitors and targeted biologics | −1.0% | North America, Europe, Japan | Medium-term (2–4 yr) | [19] |
| High therapy cost and payer utilization controls | −0.7% | North America, Europe | Short-term (≤2 yr) | [20] |
| Donor compensation limits and import dependence in Europe | −0.6% | Europe | Long-term (≥4 yr) | [5][21] |
| Thromboembolic and renal safety risks | −0.4% | Global | Long-term (≥4 yr) | [2] |

### Plasma Supply Constraints and Rising Collection Cost

The binding restriction is still plasma. Cost per liter increased by almost 25% over 2019 levels due to donor fees, labor, and testing; Grifols only started to reverse this trend in 2023 with an operational improvement plan [11]. Higher plasma costs directly affect product costs and restrict volume expansion in tight years because IgG yield per liter is set in the short term.

### Competition from FcRn Inhibitors and Targeted Biologics

argenx reported 2024 efgartigimod product sales above USD 2 billion [19], and its subcutaneous formulation gained FDA approval for CIDP in June 2024. UCB's rozanolixizumab entered myasthenia gravis in 2023. These targeted agents offer shorter administration times and compete directly for maintenance patients in neurology, the segment that drove much of IVIg's recent gram growth.

### High Therapy Cost and Payer Utilization Controls

U.S. acquisition costs commonly sit between USD 100 and 180 per gram. A 70 kg CIDP patient dosed at 1 g/kg every three weeks can exceed USD 150,000 per year. Payers respond with prior authorization, dosing to ideal body weight and periodic re-challenge requirements [20], which trims volumes per patient even as patient counts rise.

### Donor Compensation Limits and Import Dependence in Europe

The European Commission estimates that the bloc imports over 38% of its plasma for medications from the United States, and the majority of EU member states prohibit compensated donation [21]. The SoHO Regulation permits reimbursement for donor expenditures while maintaining the voluntary, unpaid principle [5]. This limits the expansion of domestic capacity and exposes European supply to disruptions in U.S. collection.

### Thromboembolic and Renal Safety Risks

In 2013, the FDA required a boxed warning for thrombosis on all human immune globulin products, adding to existing renal dysfunction warnings [2]. Reported thromboembolic event rates range from about 1% to above 10% depending on patient risk factors. Prescribers therefore limit infusion rates and screen elderly or high-risk patients, which slows uptake in some off-label uses.

## Opportunities

## Intravenous Immunoglobulin Market Opportunities

Five opportunity areas stand out for suppliers and investors in the Intravenous Immunoglobulin (IVIg) Market over 2026–2035, each tied to a specific technology, policy or geographic gap.

### Emerging-Market Fractionation and Contract Manufacturing

India, Indonesia and much of Africa discard large volumes of recovered plasma for lack of fractionation capacity [8]. Contract fractionation, in which a country ships plasma to an established fractionator and receives finished IVIg back, offers a fast route to supply. Brazil's Hemobrás plant and Egypt's Grifols venture show the model scaling, creating technology-licensing and toll-manufacturing revenue for incumbents.

### Home Infusion Services and Outcomes-Based Contracting

Specialty pharmacies and infusion networks are bundling nursing, adherence monitoring and electronic infusion logs into service contracts. The resulting real-world data on infection rates, dose adjustments and hospitalizations can support outcomes-based agreements with payers and anonymized datasets for manufacturers' label-expansion work. The permanent CMS home benefit [3] makes this a near-term business model rather than a pilot.

### High-Concentration and Faster-Infusion Formats

Twenty-percent formulations and higher maximum infusion rates reduce chair time by hours per session. For hospitals facing infusion-bed shortages, that translates into measurable capacity gains. Newer FDA-approved brands such as ALYGLO and Yimmugo [4][22] compete on tolerability and infusion speed, rewarding manufacturers that invest in formulation science.

### New Immunomodulatory Indications

In addition to prophylaxis in patients with bispecific-treated myeloma, there is growing evidence for autoimmune IVIg treatment in autoimmune encephalitis, stiff-person syndrome, and several inflammatory myopathies [16][20]. High-dose demand is increased by each indication that obtains label or guideline endorsement. Manufacturers who provide funding for randomized trials are granted exclusivity on labeling that payers are increasingly demanding.

### Gulf and North African Capacity Partnerships

Saudi Arabia's Vision 2030 localization targets and Egypt's national plasma program are attracting long-term offtake and technology-transfer agreements. Early partners secure preferred-supplier positions in fast-growing public procurement systems where demand is currently met almost entirely by imports.

## Future Outlook

## Intravenous Immunoglobulin Market Future Outlook

### Industrialized Plasma Collection and Donor Analytics

Over the next decade, growth in the Intravenous Immunoglobulin (IVIg) Market will depend on collecting more plasma at lower cost per litre. Operators are applying [predictive analytics](https://www.marketresearchfuture.com/reports/predictive-analytics-market-6845) to donor scheduling, retention and staffing, and automated devices are shortening donation time [10]. With the U.S. supplying roughly two-thirds of global fractionation plasma [6], efficiency gains there will set the global supply ceiling.

### Competitive Reset from Targeted Immunology

FcRn inhibitors, complement inhibitors and B-cell therapies will keep pressuring IVIg in myasthenia gravis and CIDP maintenance. IVIg retains advantages in acute crises, pregnancy, broad-spectrum immunomodulation and replacement therapy, where no targeted agent substitutes. Expect manufacturers to defend share through head-to-head data, faster formulations and indication-specific pricing.

### Decentralized Care and Subcutaneous Crossover

Maintenance infusions will continue moving from hospitals to clinics and homes. Takeda's HyQvia CIDP approval in January 2024 [23] shows how facilitated subcutaneous products blur the line between intravenous and home care. Suppliers that manage both formats can keep patients within their portfolio as preferences shift.

### Supply Security as Health Policy

Governments increasingly treat immunoglobulin as a strategic medicine. The European Commission's proposed Critical Medicines Act of March 2025 targets supply resilience for essential products [24], and WHO guidance encourages domestic plasma programs in lower-income countries [8]. These policies will support regional capacity, long-term offtake contracts and more diversified supply chains.

## Segment Insights

## Intravenous Immunoglobulin Market Segmentation

### By Immunoglobulin Class

| Segment | Metric (one per row) | Primary Demand Driver |
| --- | --- | --- |
| IgG | 79.2% share | Replacement and high-dose immunomodulation |
| IgA | 5.9% CAGR | Mucosal immunity research applications |
| IgM | USD 1.24 Billion | IgM-enriched preparations for severe infection |
| Others | 4.0% share | Specialty and hyperimmune preparations |

Within the Intravenous Immunoglobulin (IVIg) Market, IgG dominates because licensed products for immunodeficiency and neurology are IgG preparations [1]. IgG is also the fastest-growing class, helped by high-strength formulations and newer brands such as ALYGLO and Yimmugo [4][22]. IgA and IgM remain niche: IgM-enriched products serve sepsis and severe infection protocols in parts of Europe, while IgA use is largely limited to research and specialty preparations.

### By Application

| Segment | Metric (one per row) | Primary Demand Driver |
| --- | --- | --- |
| Hypogammaglobulinemia | 34.4% share | Established replacement guidelines |
| Chronic Inflammatory Demyelinating Polyneuropathy | USD 3.71 Billion | High maintenance doses |
| Primary Immunodeficiency | 18.6% share | Newborn screening and genetic diagnosis |
| Myasthenia Gravis | 8.45% CAGR | Earlier use in exacerbations and crises |
| Multifocal Motor Neuropathy | USD 0.92 Billion | First-line labelled therapy |
| Others | 11.3% share | Kawasaki disease, ITP, off-label neurology |

Application demand in the Intravenous Immunoglobulin (IVIg) Market is split between replacement and immunomodulation. Hypogammaglobulinemia leads through entrenched prescribing, while Primary Immunodeficiency gains from earlier diagnosis [14]. Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy generate large gram volumes per patient [15]. Myasthenia Gravis grows fastest, although FcRn inhibitors will compete hardest here [19].

### By End User

| Segment | Metric (one per row) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | 47.2% share | First infusions and acute neurology care |
| Specialty Clinics & Neurology Centers | 8.70% CAGR | Payer site-of-care steering |
| Home Care Settings | USD 2.53 Billion | CMS home IVIg benefit and nursing networks |
| Others | 7.0% share | Ambulatory surgical and physician-office infusion |

Hospitals remain the largest channel in the Intravenous Immunoglobulin (IVIg) Market because initial doses, Guillain-Barré and myasthenic crisis care require monitored settings. Specialty Clinics & Neurology Centers grow fastest as payers move stable maintenance patients to lower-cost sites. Home Care Settings are expanding under the permanent CMS benefit [3], supported by specialty pharmacy nursing networks.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (one per row) | Primary Investment Themes |
| --- | --- | --- |
| North America | 44.6% share | Plasma centre expansion, home infusion, neurology use |
| Europe | USD 4.84 Billion | Plasma self-sufficiency, tender procurement, SoHO compliance |
| Asia-Pacific | 8.9% CAGR | Domestic fractionation, diagnosis growth, contract manufacturing |
| South America | 4.6% share | Public fractionation, national procurement |
| Middle East & Africa | USD 0.64 Billion | Localization programs, technology transfer |
| Total | USD 17.67 Billion | — |

Regional demand in the Intravenous Immunoglobulin (IVIg) Market tracks plasma collection capacity, diagnosis rates and reimbursement depth.

### North America

| Country | Metric (one per row) | Key Driver |
| --- | --- | --- |
| US | 88.5% share of region | Paid-donor plasma network and CMS home IVIg benefit |
| Canada | USD 0.62 Billion | Canadian Blood Services domestic Ig supply strategy |
| Mexico | 7.6% CAGR | Consolidated public procurement through IMSS |

The United States anchors the regional Intravenous Immunoglobulin (IVIg) Market with more than 1,000 licensed collection centres [6] and the world's highest per-capita use, concentrated in neurology and primary immunodeficiency. Canada is reducing its reliance on U.S.-derived product through a 2022 agreement between Canadian Blood Services and Grifols to produce immunoglobulin from Canadian plasma. Mexico's growth comes from IMSS consolidated purchasing and better diagnosis in public hospitals.

### Europe

| Country | Metric (one per row) | Key Driver |
| --- | --- | --- |
| Germany | 24.0% share of region | Compensated donation and high per-capita neurology use |
| UK | USD 0.71 Billion | 2021 lifting of the ban on UK plasma for fractionation |
| France | 15.5% share of region | LFB state fractionation and new Arras plant |
| Italy | 5.4% CAGR | Regional toll-fractionation contracts |
| Spain | USD 0.43 Billion | Domestic fractionation by Grifols |
| Nordic Countries | 5.1% CAGR | Octapharma Stockholm capacity |
| Russia | 4.2% share of region | Import substitution policy |
| Rest of Europe | USD 0.67 Billion | Central European plasma collection |

Germany leads Europe because donors there may receive expense compensation, producing one of the continent's few plasma surpluses. In 2021, UK regulators approved domestic plasma for fractionation after a two-decade ban. France's state-owned LFB is commissioning its Arras plant to raise national self-sufficiency, and Italy relies on regional toll-fractionation. The SoHO Regulation [5] will standardize donor protection across all markets by 2027.

### Asia-Pacific

| Country | Metric (one per row) | Key Driver |
| --- | --- | --- |
| China | 38.0% share of region | Domestic fractionators and expanding plasma station licences |
| India | 11.2% CAGR | Rising diagnosis and contract fractionation initiatives |
| Japan | USD 0.71 Billion | Blood Law self-sufficiency mandate |
| South Korea | 6.5% share of region | GC Biopharma and SK Plasma export-oriented capacity |
| ASEAN | 10.1% CAGR | Indonesia's domestic plasma fractionation plant |
| Rest of Asia-Pacific | USD 0.38 Billion | Australia's national Ig governance framework |

China permits imported albumin but restricts imported IVIg, so domestic producers such as Shanghai RAAS capture nearly all national demand [17]. India is the fastest-growing country as specialist centres expand and recovered plasma moves into contract fractionation. Japan's Blood Law prioritizes domestically sourced products, and Australia's National Blood Authority governs access through national eligibility criteria [25].

### South America

| Country | Metric (one per row) | Key Driver |
| --- | --- | --- |
| Brazil | 58.0% share of region | Hemobrás public fractionation program |
| Argentina | 6.3% CAGR | UNC-Hemoderivados university fractionator |
| Rest of South America | USD 0.17 Billion | Tender-based imports |

Brazil dominates through SUS public procurement and the Hemobrás fractionation complex in Pernambuco, which aims to cut reliance on imported plasma products. Argentina's Córdoba-based UNC-Hemoderivados supplies a meaningful share of national demand from domestic plasma. Elsewhere, Chile, Colombia and Peru depend on periodic tenders, so supply and pricing swing with global availability.

### Middle East & Africa

| Country | Metric (one per row) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | USD 0.19 Billion | Vision 2030 pharmaceutical localization |
| UAE | 9.2% CAGR | Specialty hospital expansion |
| South Africa | 14.0% share of region | National Bioproducts Institute fractionation |
| Egypt | 8.1% CAGR | Grifols Egypt plasma and fractionation joint venture |
| Rest of MEA | 22.0% share of region | Donor-funded and tender procurement |

Saudi Arabia is the largest regional buyer, and its localization program is drawing technology-transfer proposals from global fractionators. South Africa's National Bioproducts Institute is one of the continent's only operating fractionators. Egypt's joint venture with Grifols should make the country a regional supply hub once local fractionation starts, while most sub-Saharan countries still rely on imports.

## Competitive Benchmarking

## Competitive Benchmarking

The Intravenous Immunoglobulin (IVIg) Market is moderately concentrated, with an estimated HHI of 1,500–1,700. The top five fractionators hold an estimated 72–78% of global revenue, owing to plasma access, licensed capacity and regulatory track record [7]. Below them sits a fragmented tier of national and regional producers, especially in China, South Korea and Europe [13][17].

| Company | Est. Revenue Share Range | Key Offerings for Intravenous Immunoglobulin (IVIg) Market | Strategic Positioning |
| --- | --- | --- | --- |
| CSL Behring | ~24–28% | Privigen, Hizentra (SC) | Largest plasma network; Rika collection automation |
| Grifols | ~18–22% | Gamunex-C, Flebogamma DIF | Vertically integrated; Biotest stake; Egypt and Canada partnerships |
| Takeda | ~16–20% | Gammagard Liquid, HyQvia | Broad IV and facilitated SC portfolio; neurology labels |
| Octapharma | ~8–11% | Octagam 10%, Panzyga | Private fractionator; dermatomyositis and CIDP labels |
| Kedrion Biopharma | ~4–6% | Kedrion IVIg, Gammaplex (BPL) | Combined Kedrion-BPL scale; toll fractionation |
| Shanghai RAAS | ~2–4% | Domestic IVIg brands | Leading Chinese fractionator |
| Biotest AG | ~2–4% | Yimmugo, Intratect | New Dreieich capacity; U.S. entry |
| LFB | ~2–3% | Clairyg, Tegeline | French state fractionator; Arras expansion |
| GC Biopharma | ~1–3% | ALYGLO | Korean producer entering U.S. |
| ADMA Biologics | ~1–3% | Asceniv, Bivigam | U.S. plasma-to-product model; yield enhancement |

## Recent News & Developments

## Recent News & Developments

Regulatory approvals, label expansions and capital deals shaped the Intravenous Immunoglobulin (IVIg) Market between 2023 and 2025.

- Grifols (December 2023): Agreed to sell a 20% stake in Shanghai RAAS to Haier for about USD 1.8 billion to reduce debt and refocus on plasma operations [11]
- CMS (January 2024): Implemented the permanent Medicare IVIG items and services benefit for home infusion in primary immunodeficiency [3]

- argenx (June 2024): Received FDA approval of subcutaneous efgartigimod for CIDP, intensifying competition in IVIg's largest neurology indication [19]
- European Union (July 2024): Published Regulation (EU) 2024/1938 on substances of human origin, reshaping plasma donor and supply oversight [5]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Global Intravenous Immunoglobulin (IVIg) Market by Immunoglobulin Class, Application, End User and Region |
| Study Period | 2021–2035 (Historical: 2021–2024; Base Year: 2025; Forecast: 2026–2035) |
| CAGR | 6.85% (2026–2035) |
| Market Size Checkpoints | USD 17.67 Billion (2025); USD 18.91 Billion (2026); USD 26.34 Billion (2031); USD 34.33 Billion (2035) |
| Fastest Growing Segments | IgG; Myasthenia Gravis; Specialty Clinics & Neurology Centers; Asia-Pacific |
| Companies Profiled | CSL Behring, Grifols, Takeda, Octapharma, Kedrion Biopharma, Shanghai RAAS, Biotest AG, LFB, GC Biopharma, ADMA Biologics |
| Valuation Currency | USD Billion |
| CAGR Driver Disclaimer | Driver and restraint impacts are directional and non-additive |

## Frequently Asked Questions

**Q: How should hospital pharmacies approach procurement in the Intravenous Immunoglobulin (IVIg) Market?**
A: Pharmacies increasingly qualify two or more brands under multi-source contracts to hedge against allocation during shortages. Brands differ in sugar stabilizers, sodium and IgA content, so formularies should map products to patient risks such as renal impairment or IgA deficiency [20].

**Q: Are IVIg brands clinically interchangeable?**
A: Not automatically. Brands in the Intravenous Immunoglobulin (IVIg) Market are licensed for different indications and vary in osmolality, pH and stabilizer chemistry. Switching should follow clinical review, because product changes have been linked to higher adverse-event rates in sensitive patients [20].

**Q: What makes new entry into the Intravenous Immunoglobulin (IVIg) Market difficult?**
A: Entry requires a secured plasma supply, a licensed fractionation plant and years of regulatory work before first revenue. A greenfield facility typically takes five to seven years to build and validate, so most entrants license technology or partner with established fractionators [8].

**Q: How does subcutaneous immunoglobulin compare with IVIg for patients?**
A: Subcutaneous products deliver steadier IgG trough levels and allow weekly self-infusion at home. IVIg remains preferred for high-dose immunomodulation, where volumes are too large for subcutaneous delivery [20].

**Q: What happens to supply during an IVIg shortage?**
A: Manufacturers move to allocation, distributing product by historical purchase volumes rather than new orders. Health systems respond with demand-management protocols that prioritize primary immunodeficiency, a model Australia formalized through national eligibility criteria [25].

**Q: What should investors watch when evaluating the Intravenous Immunoglobulin (IVIg) Market?**
A: Cost per litre of plasma and grams recovered per litre drive margins more than list price. Investors should also track albumin and alpha-1 demand, since those co-products absorb the rest of each litre [7].

**Q: Do biosimilar or recombinant alternatives threaten IVIg?**
A: No biosimilar IVIg exists because the product is a polyclonal pool from thousands of donors. Recombinant polyclonal antibodies remain in early development, so plasma-based supply should dominate the Intravenous Immunoglobulin (IVIg) Market through 2035 [20].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/intravenous-immunoglobulin-market-3137*